** Licensed Canadian cannabis producers with
well-established manufacturing and formulation expertise, such
as Organigram OGI.TO , are best-positioned to start Canada's
Cannabis 2.0 era, Raymond James analyst Rahul Sarugaser says
** Cannabis 2.0, or legalization of marijuana derivatives
including edibles, beverages, extracts and vape pens, took
effect on Thursday, with sales seen beginning in mid-December
** Canada had legalized use of recreational marijuana about
a year ago, but investors have hoped the second wave of
legislation would lift shares of pot stocks
** However, the industry faces a bottleneck as retail
outlets haven't been licensed in numbers great enough to receive
the cannabis flower and oil products being produced urn:newsml:reuters.com:*:nL3N26W3ZT
** Sarugaser says new legislation means Canada's cannabis
capital markets have begun their shift from the "buy a dream"
days of 2017-2018 to a more measured "buy a good operator" epoch
** While companies that embrace engineering principles,
invest in intellectual property and leverage foundational
scientific data will be long-term winners, new laws will be a
"nightmare" of high costs with poor sales and unprofitability
for companies with little expertise in producing - Sarugaser
** U.S.-listed shares of pot producers Canopy Growth Corp
CGC.N , CannTrust Holdings CTST.N , Tilray TLRY.O , Aurora
Cannabis ACB.N , Hexo Corp HEXO.N and Cronos Group CRON.O
rise as Cannabis 2.0 kicks off urn:newsml:reuters.com:*:nL3N27231T
(Reporting by Tamara Mathias in Bengaluru)
((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 1208;))